Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Mallinckrodt
Johnson and Johnson
Harvard Business School
Baxter

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR IOBENGUANE I-131


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Iobenguane I-131

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00126412 ↗ Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed GE Healthcare Phase 3 2005-08-02 The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
NCT00126425 ↗ Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease Completed GE Healthcare Phase 3 2005-07-01 The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.
NCT00126438 ↗ Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease Completed GE Healthcare Phase 3 2005-07-01 The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease.
NCT00339131 ↗ ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Completed Molecular Insight Pharmaceuticals, Inc. Phase 1 2006-06-01 The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much radioactivity is absorbed into different tissues of the body.
NCT00458952 ↗ Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed Molecular Insight Pharmaceuticals, Inc. Phase 1/Phase 2 2007-04-01 The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
NCT00659984 ↗ N2007-01: Ultratraceā„¢ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma Completed Molecular Insight Pharmaceuticals, Inc. Phase 2 2008-06-01 RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIBG), may carry radiation directly to tumor cells and not harm normal cells. A bone marrow or peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by I 131 MIBG. PURPOSE: This phase II trial is studying the side effects and best dose of iodine I 131 MIBG followed by a stem cell transplant in treating young patients with relapsed or refractory high-risk neuroblastoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iobenguane I-131

Condition Name

Condition Name for Iobenguane I-131
Intervention Trials
Neuroblastoma 7
Pheochromocytoma 4
Ganglioneuroblastoma 3
Paraganglioma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Iobenguane I-131
Intervention Trials
Neuroblastoma 9
Pheochromocytoma 4
Heart Failure 4
Ganglioneuroblastoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Iobenguane I-131

Trials by Country

Trials by Country for Iobenguane I-131
Location Trials
United States 120
Canada 6
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Iobenguane I-131
Location Trials
North Carolina 7
Texas 7
Pennsylvania 7
Illinois 6
California 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Iobenguane I-131

Clinical Trial Phase

Clinical Trial Phase for Iobenguane I-131
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 2 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Iobenguane I-131
Clinical Trial Phase Trials
Completed 9
Recruiting 3
Approved for marketing 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Iobenguane I-131

Sponsor Name

Sponsor Name for Iobenguane I-131
Sponsor Trials
GE Healthcare 5
Molecular Insight Pharmaceuticals, Inc. 5
National Cancer Institute (NCI) 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Iobenguane I-131
Sponsor Trials
Industry 13
Other 6
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Medtronic
Mallinckrodt
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.